Novartis

News

Roche set to file ophthalmology drug faricimab in DME

Roche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody showed comparable results in diabetic macular oedema (DME) but with half the in

News

FDA rejects Novartis' cholesterol drug after factory inspect...

Novartis’ cholesterol drug inclisiran has hit a speed bump with the FDA, which has rejected the potential blockbuster because a manufacturing facility has yet to be inspected.

News

Novartis buys neurology biotech Cadent for up to $770m

Novartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million.

News

Entresto set for big sales hike after FDA panel endorsement

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a ph

News

Novartis/Incyte draw blank with Jakafi in COVID-19

Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against COVID-19, after it failed to cut complications or death in a phase 3 tria

News

Novartis signs ophthalmology AI deal with RetinAI

Novartis has signed a multi-year agreement with RetinAI, which will see the companies work together to use artificial intelligence (AI) tools to support ophthalmology and digital health pro

Roche set to file ophthalmology drug faricimab in DME

FDA rejects Novartis' cholesterol drug after factory inspect...

Novartis buys neurology biotech Cadent for up to $770m

Entresto set for big sales hike after FDA panel endorsement

Novartis/Incyte draw blank with Jakafi in COVID-19

Novartis signs ophthalmology AI deal with RetinAI

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Novartis

Editor's Picks